Indication for relumpectomya useful scoring system in cases of invasive breast cancer

Ariel Halevy*, Ron Lavy, Itzhak Pappo, Tima Davidson, Ruth Gold-Deutch, Igor Jeroukhimov, Zahar Shapira, Ilan Wassermann, Judith Sandbank, Bar Chikman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background and Objectives In two-thirds of breast cancer patients undergoing reoperation no residual tumor will be found. A scoring system for selection of patients who might benefit from relumpectomy is proposed. Methods This study is based on 293 patients with invasive breast cancer undergoing reoperation due to margins of <2mm. Eighteen parameters were evaluated by univariate and multivariate stepwise logistic regression. Results Univariate analysis identified nine parameters associated with a residual invasive tumor: surgical margins; lobular histological type; grade 3; multifocality; positive lymph modes; non-fine needle localization (FNL) versus FNL lumpectomy; vascular/lymphatic invasion; age <50 years; and tumor size ≤yen;3cm. Multivariate stepwise logistic regression study identified six out of nine parameters associated with a higher probability of finding a residual invasive tumor: margins <1mm, multifocality, tumor size ≤yen;3cm, positive lymph nodes, age <50 years, and lumpectomy without previous FNL. Odds of these factors were used for scoring. Conclusions For patients with surgical margins <2mm and a score of <4, the probability of finding a residual invasive tumor is 0%, while the probability of finding a microfocus of <2mm of invasive carcinoma is 3.2% and of finding residual DCIS is up to 10%.

Original languageEnglish
Pages (from-to)376-380
Number of pages5
JournalJournal of Surgical Oncology
Volume105
Issue number4
DOIs
StatePublished - 15 Mar 2012
Externally publishedYes

Keywords

  • breast cancer
  • lumpectomy
  • relumpectomy
  • scoring system

Fingerprint

Dive into the research topics of 'Indication for relumpectomya useful scoring system in cases of invasive breast cancer'. Together they form a unique fingerprint.

Cite this